Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study to Evaluate the Efficacy and Safety of Cisplatin or Carboplatin / Etoposide and Concomitant Radiotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab Versus Cisplatin or Carboplatin / Etoposide and Concomitant Radiotherapy in Patients With Limited Disease Small Cell Lung Cancer

NCT04602533 is registered in ClinicalTrials.gov with Michael Hopp as lead sponsor.

NCT NCT04602533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study to Evaluate the Efficacy and Safety of Cisplatin or Carboplatin / Etoposide and Concomitant Radiotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab Versus Cisplatin or Carboplatin / Etoposide and Concomitant Radiotherapy in Patients With Limited Disease Small Cell Lung Cancer
Lead sponsor
Michael Hopp
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 21, 2020
Completion date
December 31, 2026
Enrollment
105 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer limited stage